HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome: External Validation on Safe Implementation of Thrombolysis in Stroke-Monitoring Study Data.

AbstractBACKGROUND AND PURPOSE:
National Institutes of Health Stroke Scale (NIHSS) item profiles that were recently proposed and validated may prove useful for clinical prognostication and research studies. We aimed to validate the NIHSS item profiles in hyper-acute stroke patients who received thrombolysis treatment (tissue-type plasminogen activator).
METHODS:
We applied the latent class analysis probabilities of the profile membership generated from the derivation study onto NIHSS data from the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). We separately considered NIHSS data collected within 3 hours and at ≈24 hours after stroke onset to obtain 2 sets of symptom groupings. The discrimination and calibration of both sets of symptom profiles were assessed from their association with outcomes. The outcome measures included modified Rankin Scale (mRS; using full distribution and dichotomized, mRS 0-1 or back to baseline) at day 90 and mortality by 90 days.
RESULTS:
We obtained data for 6843 patients. Ordinal analysis of mRS showed odds of better outcome across the profiles, for each set of symptom profiles, adjusted for age, sex, and prestroke mRS. Dichotomized outcomes mirrored the ordinal findings. There were significant differences in prognostic discrimination ability for the dichotomized outcome measures between the 2 sets of symptom profiles, with the latter set (ie, 24-hour symptom profiles) performing better.
CONCLUSIONS:
The NIHSS item profiles are individually associated with functional outcome and mortality in acute stroke patients treated with tissue-type plasminogen activator. Considering profiles of NIHSS subscores rather than only the total score is informative for prognostication, particularly for assessments collected 24 hours after stroke onset.
AuthorsAzmil H Abdul-Rahim, Rachael L Fulton, Heidi Sucharew, Dawn Kleindorfer, Pooja Khatri, Joseph P Broderick, Kennedy R Lees, SITS-MOST Steering Committee
JournalStroke (Stroke) Vol. 46 Issue 10 Pg. 2779-85 (Oct 2015) ISSN: 1524-4628 [Electronic] United States
PMID26359360 (Publication Type: Journal Article, Validation Study)
Copyright© 2015 American Heart Association, Inc.
Chemical References
  • Fibrinolytic Agents
Topics
  • Aged
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • National Institutes of Health (U.S.)
  • Product Surveillance, Postmarketing
  • Retrospective Studies
  • Stroke (drug therapy)
  • Thrombolytic Therapy
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: